Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions

被引:107
作者
Kalkman, Deborah N. [1 ,2 ]
Aquino, Melissa [1 ]
Claessen, Bimmer E. [1 ]
Baber, Usman [1 ]
Guedeney, Paul [1 ]
Sorrentino, Sabato [1 ]
Vogel, Birgit [1 ]
de Winter, Robbert J. [2 ]
Sweeny, Joseph [1 ]
Kovacic, Jason C. [1 ]
Shah, Srushti [1 ]
Vijay, Pooja [1 ]
Barman, Nitin [1 ]
Kini, Annapoorna [1 ]
Sharma, Samin [1 ]
Dangas, George D. [1 ]
Mehran, Roxana [1 ]
机构
[1] Icahn Sch Med Mt Sinai Hosp, Ctr Intervent Cardiovasc Res & Clin Trials, One Gustave L Levy Pl Box 1030, New York, NY 10029 USA
[2] Univ Amsterdam, Heart Ctr, Amsterdam Cardiovasc Sci, Dept Clin & Expt Cardiol,Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
关键词
Percutaneous coronary intervention; Inflammation; C-reactive protein; Clinical outcomes; All-cause mortality; C-REACTIVE PROTEIN; DUAL ANTIPLATELET THERAPY; CARDIOVASCULAR EVENTS; ARTERY-DISEASE; FOCUSED UPDATE; ELEVATION; ASSOCIATION; INFARCTION; REDUCTION;
D O I
10.1093/eurheartj/ehy633
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims It remains unknown what percentage of patients treated with percutaneous coronary artery intervention (PCI) have high residual inflammatory risk (RIR). Moreover, the impact of RIR on clinical outcomes has not been established. The objective of this study is to determine the prevalence of patients with persistent high levels of inflammation after PCI and to evaluate clinical outcomes according to inflammatory response. Methods and results This is a retrospective cohort study assessing patients undergoing PCI between 2009 and 2016 with serial inflammatory status assessment from a large, prospective, and single-centre PCI registry. Assessment of inflammation status with at least two high sensitive C-reactive protein (hsCRP) measurements at baseline and follow-up with >4 weeks apart. High RIR was defined as an hsCRP >= 2 mg/L. Patients were divided into four groups: persistent high RIR, increased RIR (first low-, then high hsCRP), attenuated RIR (first high-, then low hsCRP), or persistent low RIR. The primary endpoint was all-cause mortality at 1 year follow-up. Occurrence of myocardial infarction (MI) was assessed as secondary outcome. Seven thousand and twenty-six patients were identified with serial hsCRP measurements (30.8% of all PCI patients). Of these patients 2654 (38%) had persistent high RIR, 719 patients (10%) had increased RIR, 1088 patients (15%) had attenuated RIR, and persistent low RIR was seen in 2565 patients (37%). All-cause mortality at 1 year was 2.6% in patients with persistent high RIR, compared with 1.0% in increased RIR, 0.3% in attenuated RIR, and 0.7% in persistent low RIR patients, P < 0.01. MI at 1 year was observed in 7.5% of persistent high RIR, compared with 6.4% in increased RIR, 4.6% in attenuated RIR, and 4.3% in persistent low RIR, P < 0.01. In an adjusted model, including accounting for diabetes mellitus, acute coronary syndrome, and baseline low-density lipoprotein, results were sustained. Conclusion Persistent high RIR is observed frequently in patients undergoing PCI. In these patients, significantly higher all-cause mortality and MI rates are observed at 1 year follow-up. Residual inflammatory risk in patients undergoing PCI should be identified and treatment options should be further explored.
引用
收藏
页码:4101 / +
页数:9
相关论文
共 27 条
  • [11] Sex Differences in Inflammatory Markers and Health Status Among Young Adults With Acute Myocardial Infarction Results From the VIRGO (Variation in Recovery: Role of Gender on Outcomes of Young Acute Myocardial Infarction Patients) Study
    Lu, Yuan
    Zhou, Shengfan
    Dreyer, Rachel P.
    Spatz, Erica S.
    Geda, Mary
    Lorenze, Nancy P.
    D'Onofrio, Gail
    Lichtman, Judith H.
    Spertus, John A.
    Ridker, Paul M.
    Krumholz, Harlan M.
    [J]. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2017, 10 (02):
  • [12] Preprocedural C-Reactive Protein Predicts Outcomes after Primary Percutaneous Coronary Intervention in Patients with ST-elevation Myocardial Infarction a systematic meta-analysis
    Mincu, Raluca-Ileana
    Janosi, Rolf Alexander
    Vinereanu, Dragos
    Rassaf, Tienush
    Totzeck, Matthias
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [13] Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients
    Mueller, C
    Buettner, HJ
    Hodgson, JM
    Marsch, S
    Perruchoud, AP
    Roskamm, H
    Neumann, FJ
    [J]. CIRCULATION, 2002, 105 (12) : 1412 - 1415
  • [14] High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention
    Oemrawsingh, Rohit M.
    Cheng, Jin M.
    Akkerhuis, K. Martijn
    Kardys, Isabella
    Degertekin, Muzaffer
    van Geuns, Robert-Jan
    Daemen, Joost
    Boersma, Eric
    Serruys, Patrick W.
    van Domburg, Ron T.
    [J]. EUROINTERVENTION, 2016, 12 (03) : 345 - 351
  • [15] A Point-of-Care Platelet Function Assay and C-Reactive Protein for Prediction of Major Cardiovascular Events After Drug-Eluting Stent Implantation
    Park, Duk-Woo
    Lee, Seung-Whan
    Yun, Sung-Cheol
    Song, Hae-Geun
    Ahn, Jung-Min
    Lee, Jong-Young
    Kim, Won-Jang
    Kang, Soo-Jin
    Kim, Young-Hak
    Lee, Cheol Whan
    Park, Seong-Wook
    Park, Seung-Jung
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (25) : 2630 - 2639
  • [16] C-Reactive Protein and the Risk of Stent Thrombosis and Cardiovascular Events After Drug-Eluting Stent Implantation
    Park, Duk-Woo
    Yun, Sung-Cheol
    Lee, Jong-Young
    Kim, Won-Jang
    Kang, Soo-Jin
    Lee, Seung-Whan
    Kim, Young-Hak
    Lee, Cheol Whan
    Kim, Jae-Joong
    Park, Seong-Wook
    Park, Seung-Jung
    [J]. CIRCULATION, 2009, 120 (20) : 1987 - U29
  • [17] 2016 European Guidelines on cardiovascular disease prevention in clinical practice
    Piepoli, Massimo F.
    Hoes, Arno W.
    Agewall, Stefan
    Albus, Christian
    Brotons, Carlos
    Catapano, Alberico L.
    Cooney, Marie-Therese
    Corra, Ugo
    Cosyns, Bernard
    Deaton, Christi
    Graham, Ian
    Hall, Michael Stephen
    Hobbs, F. D. Richard
    Lochen, Maja-Lisa
    Loellgen, Herbert
    Marques-Vidal, Pedro
    Perk, Joep
    Prescott, Eva
    Redon, Josep
    Richter, Dimitrios J.
    Sattar, Naveed
    Smulders, Yvo
    Tiberi, Monica
    van der Worp, H. Bart
    van Dis, Ineke
    Verschuren, W. M. Monique
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (29) : 2315 - +
  • [18] High-sensitivity C-reactive protein levels and health status outcomes after myocardial infarction
    Pokharel, Yashashwi
    Sharma, Puza P.
    Qintar, Mohammed
    Lu, Yuan
    Tang, Yuanyuan
    Jones, Philip
    Dreyer, Rachel P.
    Spertus, John A.
    [J]. ATHEROSCLEROSIS, 2017, 266 : 16 - 23
  • [19] Prevalence and predictors of elevated high-sensitivity C-reactive protein in post-myocardial infarction patients: Insights from the VIRGO and TRIUMPH registries
    Qintar, Mohammed
    Sharma, Puza P.
    Pokharel, Yashashwi
    Tang, Yuanyuan
    Lu, Yuan
    Jones, Philip
    Dreyer, Rachel P.
    Spertus, John A.
    [J]. CLINICAL CARDIOLOGY, 2017, 40 (12) : 1205 - 1211
  • [20] Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
    Ridker, P. M.
    Everett, B. M.
    Thuren, T.
    MacFadyen, J. G.
    Chang, W. H.
    Ballantyne, C.
    Fonseca, F.
    Nicolau, J.
    Koenig, W.
    Anker, S. D.
    Kastelein, J. J. P.
    Cornel, J. H.
    Pais, P.
    Pella, D.
    Genest, J.
    Cifkova, R.
    Lorenzatti, A.
    Forster, T.
    Kobalava, Z.
    Vida-Simiti, L.
    Flather, M.
    Shimokawa, H.
    Ogawa, H.
    Dellborg, M.
    Rossi, P. R. F.
    Troquay, R. P. T.
    Libby, P.
    Glynn, R. J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (12) : 1119 - 1131